comprehensive -WSS

comprehensive

author：hotspot 2025-10-02 19:15:42 - browse：512

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Kaiser's Risant Health gobbled up Geisinger. Who is next?

WSS

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Oprah kicked off a national conversation on obesity. Let's have it

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

NIH documents show early flaws of $1.6 billion long Covid program

With trial win, GSK could get blood cancer drug back on market

hotspot

comprehensive

Wikipedia

New air purifier tech could be key to improving indoor air quality

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

With trial win, GSK could get blood cancer drug back on market

How one medical school became remarkably diverse

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Abortion pill Supreme Court ruling could impact entire drug industry

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

hotspot

Vertex Pharmaceuticals may move headquarters in Boston

Study says nonprofit hospitals fall short in charity care spending

ASCO: AstraZeneca says CAR

Covid vaccine financial winners and losers, from Pfizer to Novavax

Donor acceptance rates hint at racial, gender bias in heart transplants: study

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

focus

explore

leisure time

Wikipedia